This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary KIT Therapeutic Antibody Development
Background of KIT
Mutations and abnormal expressions of KIT are closely associated with the development and worsening of tumors in the veterinary field. Hence, antibodies targeting KIT provide new strategies and hope for treating these diseases. BioVenic offers comprehensive veterinary KIT therapeutic antibody development services, covering the entire process from antibody preparation to later-stage validation. Our complete development services assist in advancing projects, bringing more effective cancer treatment options for companion animals.
Background of KIT
| Full Name | KIT proto-oncogene receptor tyrosine kinase. |
|---|---|
| Aliases | CD117, C-Kit, MASTC, PBT, SCFR. |
| Target Profile | KIT is a member of the type III receptor tyrosine kinase family, widely expressed in various cell types, especially in hematopoietic cells, germ cells, and melanocytes. KIT and other type III receptor tyrosine kinases are crucial components of cellular signal transduction, responsible for maintaining cell functions such as cell survival, metabolism, growth and progression, proliferation, apoptosis, migration, and differentiation. These functions are also significant for cancer development. |
MoA of KIT
KIT is activated through binding to its ligand, stem cell factor (SCF), thereby triggering various intracellular signaling pathways, such as JAK/STAT, RAS/MAPK, PI3K/AKT, and PLCγ/PKC, which play key roles in cell proliferation, differentiation, and survival. The binding of SCF induces rapid activation of JAK and stimulates phosphorylation of STAT, regulating transcription of target genes responsible for cell proliferation in the cell nucleus. When KIT recruits adaptor proteins containing the Shc domain, the RAS/MAPK kinase cascade is activated, regulating cell proliferation, apoptosis, differentiation, adhesion, and migration. The PI3K pathway is responsible for the activity of AKT and mTOR; AKT interacts with the pro-apoptotic factor BAD, leading to its inactivation and thus promoting cell survival. PLCγ can bind to phosphorylated residues of KIT, activating PKC, which plays a role in cell survival, proliferation, and adhesion, also a crucial step in cancer development.
Fig.1 Schematic diagram of KIT signaling pathways.1
Application in Veterinary Therapeutics
KIT is closely associated with certain types of companion animal cancers, particularly canine mast cell tumors. Mast cell tumors are one of the most common types of cancer in canines, often linked to mutations in the KIT gene. Moreover, KIT is largely conserved across species, suggesting the potential of targeted KIT therapies, such as veterinary KIT therapeutic antibodies, for treating certain companion animal tumors that express or have mutations in KIT.
Veterinary KIT Therapeutic Antibody Development Services
BioVenic provides veterinary KIT therapeutic antibody development services. Our services encompass the entire process from gene synthesis to the final antibody sample, including antibody design, preparation, purification, and detailed bioactivity validation. Utilizing advanced technologies like hybridoma, single B cell, and phage display techniques, we maintain strict quality control throughout the development process to ensure the development of antibodies with high affinity and specificity. Additionally, we offer species-specific antibody development services, assisting in providing tailored solutions for different companion animal species.
Please click the link below for more information about our veterinary KIT therapeutic antibody development services.
Why Choose Us?
Our team is experienced in various aspects of veterinary therapeutic antibody development services, including animal immunology, gene synthesis, antibody preparation, purification, and characterization, offering comprehensive and reliable solutions.
We possess the capability for antibody caninization or felinization and offering affinity maturation services, ensuring high-affinity veterinary therapeutic antibodies are provided, maintaining their potential therapeutic effects.
Strict quality control is applied throughout our antibody development process. Through analysis and testing of antibody purity and stability, we promptly identify issues, ensuring the high quality of antibody samples.
The overactivation of KIT due to mutations can promote uncontrolled proliferation and survival of tumor cells, making KIT a significant target for companion animal cancer targeted therapies. BioVenic offers veterinary KIT therapeutic antibody development services, assisting in developing targeted veterinary therapeutic antibodies against KIT to inhibit aberrantly activated signaling pathways and explore the potential to control tumor growth and spread. If you are interested in our services, please contact us for more information!
References
- Foster, Brittni M., et al. "CD117/c-kit in cancer stem cell-mediated progression and therapeutic resistance." Biomedicines 6.1 (2018): 31.
- Alfaleh, Mohamed A., et al. "Canine CD117-specific antibodies with diverse binding properties isolated from a phage display library using cell-based biopanning." Antibodies 8.1 (2019): 15.